PPARD and metabolic syndrome: In the present study, we used a synthetic PPARβ/δ-specific agonist, GW501516, that has been used in research of physiological and pathophysiological functions of PPARβ/δ in conditions including obesity, diabetes, dyslipidemia, and cardiovascular disease [15,16,17].